Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Multiple Myeloma 265Leukemia, Lymphocytic, Chronic, B-Cell 66Lymphoma, Large B-Cell, Diffuse 60Neoplasms, Plasma Cell 50Lymphoma, Follicular 45Lymphoma, Mantle-Cell 42Lymphoma 41Recurrence 38Lymphoma, B-Cell, Marginal Zone 31Leukemia 30Leukemia, Myeloid, Acute 27Lymphoma, B-Cell 19Lymphoma, Non-Hodgkin 17Myelodysplastic Syndromes 16Waldenstrom Macroglobulinemia 15Smoldering Multiple Myeloma 13Hodgkin Disease 13Lymphoma, T-Cell, Peripheral 12Neoplasms 11Lymphoma, T-Cell 9Prostatic Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, T-Cell, Cutaneous 8Immunoglobulin Light-chain Amyloidosis 8Burkitt Lymphoma 8Sezary Syndrome 7Neoplasm, Residual 7Mycosis Fungoides 7Lymphoma, Large-Cell, Anaplastic 7Leukemia, Plasma Cell 6

Interventions

Brentuximab Vedotin 2Salvia hispanica seed extract 1Lenalidomide 1Cholecalciferol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Primary Cutaneous Anaplastic Large Cell × Lenalidomide × Clear all
NCT03409432 2025-07-25

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
26 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡